The genetics of healthy ageing and cancer

We're living longer. That means that we're all at greater risk of cancer and we'll all suffer from bone loss. And for many of us, our final years will be difficult.

Josef Penninger plans to change all that. His vision is of a future where we can safely surf and live active lives at 85 years of age without fear of fracture, cancer or any of the other scourges of ageing. He's director of Austria's Institute of Molecular Biotechnology, and is in Australia as a guest of the Centenary Institute in Sydney to share his vision for a healthy old age, and discuss the research that's getting us there.

More than a decade ago Professor Penninger proved that a protein called RANKL is the master regulator of . That work led to a new drug now used for treating osteoporosis and skeletal related events associated with cancer.

He then showed that the same protein is involved in sex hormone driven lactation in pregnancy.

He later showed that RANKL is a key driver of breast cancer initiation in response to , thus providing a molecular connection between hormone replacement therapies, the Pill, and .

In his latest work he's identified a molecular brake that can turn on so called , a component of the immune system.
"Our immune systems are built to see and respond to danger," he says.

"Inflammation is a key response. But as we get older the immune system's own inflammatory response starts to cause problems. At the same time the struggles to recognise cancer and respond."

Last month, he and his colleagues reported in Nature that a molecule called Cbl-b stops natural killer cells from recognising and killing cells. By turning that molecule off, his laboratory showed that the killer cells could get on with their job and markedly reduce the spread or metastasis of .

All of this work is in mice, but bodes well for a new generation of drugs to help our immune systems better cope with the challenges of ageing, and for a future in which we age healthily then die without years of chronic disease.

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Immune checkpoint inhibitors may work in brain cancers

Nov 21, 2014

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

New model of follow up for breast cancer patients

Nov 21, 2014

Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.